MAP Pharmaceuticals, Inc.
 (MAPP)

- NASDAQ
MAPP is defunct since March 4, 2013. acquired by a private company
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Jan. 23, 2013, 12:45 PM
    Midday top 10 gainers: MAPP +59%. HMNF +34%. JAXB +26%. CREE +19%. DQ +18%. THLD +16%. KERX +15%. SMCI +15%. SILC +14%. FSGI +14%.
    Midday top 10 Losers: STRI -25%. COH -15%. NMRX -15%. STSI -14%. URRE -12%. FU -12%. IAG -11%. GVP -10%. TTM -10%. VLTR -10%.
    | Jan. 23, 2013, 12:45 PM
  • Jan. 23, 2013, 9:10 AM
    Premarket gainers: MAPP +59%. TELK +23%. CREE +14%. ISRG +9%. RFMD +6%. ACAD +6%. GOOG +5%.
    Losers: COH -17%. MCP -14%. NMRX -14%. STSI -11%. BNNY -8%. GD -5%
    | Jan. 23, 2013, 9:10 AM | 1 Comment
  • Nov. 23, 2012, 1:21 PM
    Shares of MAP Pharmaceuticals (MAPP) soared today, finishing up over +20% after the company announced that the FDA accepted its Levadex resubmission with a six-month review.
    | Nov. 23, 2012, 1:21 PM
  • Nov. 23, 2012, 12:45 PM
    Midday top 10 gainers: CCCL +42%. MAPP +21%. BGMD +21%. MCP +18%. INUV +16%. FIZZ +15%. ROSG +14%. DAC +13%. RIMM +13%. RIC +12%.
    Top 10 Losers: KITD -64%. PTGI -17%. SGOC -12%. HDSN -9%. TELK -9%. SAB -8%. HRT -8%. NFEC -8%. THQI -7%. RCON -7%.
    | Nov. 23, 2012, 12:45 PM | 1 Comment
  • Nov. 23, 2012, 9:10 AM
    Premarket gainers: ALU +18%. MAPP +14%. RIMM +11%. CIG +10%. SBS +7%. NBG +5%.
    Losers: KITD -55.56%.
    | Nov. 23, 2012, 9:10 AM | 1 Comment
  • Aug. 1, 2012, 1:55 PM

    Shares of MAP Pharmaceuticals (MAPP -5.3%) slide today after the company priced its secondary offering of 3.88M shares at $13.40, a 5% discount to yesterday's close. The company intends to use the proceeds to bring its investigational migraine drug Levadex to market, as well as for other general corporate purposes.

    | Aug. 1, 2012, 1:55 PM
  • Aug. 1, 2012, 9:15 AM
    Premarket gainers: SIMG +28%. LH +13%. BPI +12%. VG +9%. GNW +8%. FTR +7%. PC +7%. GRMN +6%. DGX +6%.
    Losers: CECO -20%. DRIV -17%. TRLG -15%. ARRY -13%. NICE -13%. ENR -10%. HZNP -9%. DWA -7%. SAVE -6%. IDIX -6%. MAPP -6%. STP -5%.
    | Aug. 1, 2012, 9:15 AM
  • Apr. 13, 2012, 11:17 AM

    Map Pharmaceuticals (MAPP -2.7%) says it plans to meet with the FDA during the current quarter to discuss manufacturing issues that are hindering the approval of its migraine medication Levadex.

    | Apr. 13, 2012, 11:17 AM
  • Mar. 27, 2012, 9:03 AM

    Premarket gainers: OPXT +55%. WNC +9%. ISTA +8%. DANG +5%. RBS +3%. ARNA +3%. LEN +3%.
    Losers: MAPP -17%. MMR -16%. APOL -6%. NBG -6%. TOT -6%. OCLR -3%. EXPE -3%. HEK -3%. EXXI -3%.

    | Mar. 27, 2012, 9:03 AM
  • Mar. 27, 2012, 8:34 AM

    JPMorgan tries to make sense out of all the drama with MAP Pharmaceuticals (MAPP), by taking the long view that Levadex is an "attractive, approvable product" despite missing out on first-pass FDA approval. Shares have been on a roller coaster ride since the FDA issued a complete response letter after the market closed yesterday, sitting as high as +7% and as low as -30% before settling back to trade -18.3% premarket. Stay tuned.

    | Mar. 27, 2012, 8:34 AM
  • Mar. 27, 2012, 7:28 AM

    Shares of MAP Pharmaceuticals (MAPP) nosedive after coming off of a trading halt and are now down 28.8% after ringing up a tidy AH gain yesterday. Though the company landed FDA approval for Levadex, a number of questions concerning its disclosures and ability to bring the migraine treatment to the market still linger.

    | Mar. 27, 2012, 7:28 AM
  • Mar. 26, 2012, 8:40 PM

    MAP Pharmaceuticals (MAPP) says the FDA has issued a Complete Response letter to its New Drug Application for Levadex. The FDA didn't cite clinical safety or efficacy issues, nor request any additional clinical studies be conducted prior to approval. It did however, request the company address issues relating to chemistry, manufacturing and controls and observations from a recent facility inspection of a third party manufacturer. Shares +7% AH.

    | Mar. 26, 2012, 8:40 PM | 3 Comments
Company Description
MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the potential acute treatment of migraine. The U.S. Food and... More